By Nigam Arora Guardant Health Inc. (GH), a cancer-detection company that The Arora Report recommended at an average price of $26.34, is trading at $161.26 as of this writing after jumping over 10% following the release of its second-quarter results, bringing the gain for members who followed the signal to approximately
By Nigam Arora 245% Gain Guardant Health (GH) is long from $26.34. It is trading at $91.02 as of this writing, representing a 245% gain. Buyout Target GH is a buyout target. Cancer Screening Guardant Health is using advanced blood-based liquid biopsy tests and large clinical data sets to transform how
By Nigam Arora Editor’s note: This post was published yesterday in The Arora Report paid feeds as an Afternoon Capsule. To gain an edge, this is what you need to know now. December Not A Done Deal Please click here for a chart of S&P 500 ETF (SPY) which represents the
By Nigam Arora This post was published yesterday in The Arora Report paid feeds as an Afternoon Capsule. To gain an edge, this is what you need to know now. Two Fed Governors Dissent Please click here for a chart of S&P 500 ETF (SPY) which represents the benchmark stock market